Table 3.
Evolution of drug, antidrug antibody concentration and clinical response in one patient
| Time after start of UST therapy | UST concentration (μg mL−1) | AUA concentration: drug‐sensitive assay | AUA concentration: drug‐tolerant assay | PASI |
|---|---|---|---|---|
| Week 0 | NA | NA | NA | 26·2 |
| Week 16 | NA | NA | NA | 2·9 |
| Week 28 | < 0·25 | 138 | 235 | 6·3 |
| Week 37 (= intermediate) | < 0·25 | 52 | 155 | 9·1 |
| Week 40 | < 0·25 | 83 | 190 | 13·4 |
All anti‐ustekinumab antibody concentrations are expressed in ng mL−1 MA‐UST37F12 equivalents. UST, ustekinumab; AUA, anti‐ustekinumab antibody; PASI, Psoriasis Area Severity Index; NA, not available.